Literature DB >> 16304457

Update of the drug resistance mutations in HIV-1: Fall 2005.

Victoria A Johnson1, Francoise Brun-Vezinet, Bonaventura Clotet, Brian Conway, Daniel R Kuritzkes, Deenan Pillay, Jonathan M Schapiro, Amalio Telenti, Douglas D Richman.   

Abstract

The International AIDS Society-USA (IAS-USA) Drug Resistance Mutations Group is marking 5 years as an independent volunteer panel of experts focused on identifying key HIV-1 drug resistance mutations. The goal of the effort is to quickly deliver accurate and unbiased information on these mutations to HIV clinical practitioners. The October/November 2005 version of the IAS-USA Drug Resistance Mutations Figures replaces the version published in this journal in March/April 2005. The IAS-USA Drug Resistance Mutations Figures are designed for use in identifying mutations associated with viral resistance to antiretroviral drugs and in making therapeutic decisions. Care should be taken when using this list of mutations for surveillance or epidemiologic studies of transmission of drug-resistant virus. A number of amino acid substitutions, particularly minor mutations, represent polymorphisms that in isolation may not reflect prior drug selective pressure or reduced drug susceptibility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304457

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  36 in total

1.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

Review 2.  Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Authors:  Mark A Boyd; Andrew M Hill
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Antiretroviral treatment of HIV infected adults.

Authors:  Steven G Deeks
Journal:  BMJ       Date:  2006-06-24

4.  Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Authors:  Kathryn M Kitrinos; Heather Amrine-Madsen; David M Irlbeck; J Michael Word; James F Demarest
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

5.  Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

Authors:  James F Demarest; Heather Amrine-Madsen; David M Irlbeck; Kathryn M Kitrinos
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus type 1 sequence mutation at a population level.

Authors:  Golo Ahlenstiel; Kirsten Roomp; Martin Däumer; Jacob Nattermann; Martin Vogel; Jürgen K Rockstroh; Niko Beerenwinkel; Rolf Kaiser; Hans-Dieter Nischalke; Tilman Sauerbruch; Thomas Lengauer; Ulrich Spengler
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

7.  Cooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.

Authors:  Jennifer E Foulkes-Murzycki; Christina Rosi; Nese Kurt Yilmaz; Robert W Shafer; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2012-12-27       Impact factor: 5.100

8.  A Perturbation Method for Inference on Regularized Regression Estimates.

Authors:  Jessica Minnier; Lu Tian; Tianxi Cai
Journal:  J Am Stat Assoc       Date:  2012-01-24       Impact factor: 5.033

Review 9.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome.

Authors:  Marcin Kierczak; Krzysztof Ginalski; Michał Dramiński; Jacek Koronacki; Witold Rudnicki; Jan Komorowski
Journal:  Bioinform Biol Insights       Date:  2009-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.